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Abstract 
Objective : To evaluate the clinical usefulness of laughter yoga for patients with chronic 
obstructive pulmonary disease (COPD) in a pulmonary rehabilitation setting. 
Design : Pilot study, with randomization of participants. 
Setting: This study was conducted by the Yoshino-cho National Health Insurance Y oshino 
Hospital Department of Internal Medicine. 
Participants : Stable outpatients with COPD (7 men and 1 woman, age 64 to 84 years) 
participated in the pulmonary rehabilitation program during a 2-week period. 
Intervention : The patients were divided into two groups based on a sealed envelope 
randomization method. The laughter yoga group had a 10-min laughter yoga session before 
exercise training. Patients in both groups had exercise training, educational programs, lung 
physiotherapy, and nutrition counseling. 
Outcome Measures : Health-related qualit y of life using the St . George's Respir atory 
Questionnaire (SGRQ) and the Medical Research Council (MRC) Health Survey Short Form 36-
item (SF-36), depression scores using the Self-rating Depression Scale (SDS), anxiety scores 
using State-Trait Anxiety Inventory (STAI), and spirometry, the 6-minute walk test and mMRC 
dyspnea scale results were evaluated before and at 2 weeks after the program in both groups. 
Results : There were significant improvements in the SGRQ impacts domain and the SF-36 
general health domain in the laughter yoga group, while the SF-36 physical functioning domain 
significantly improved in the control group. SDS and ST AI result clid not significantly change 
in either group. Spirometry, the 6-minute walk test, and MRC dyspnea scale results did not 
significantly change in either group. 
Conclusion : Laughter yoga may improve the psychological quality of life in patients with 
COPD. 
Key words : chronic obstructive pulmonary disease, pulmonary rehabilitation, laughter yoga, psychological 
quality of life, depression, anxiety 
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Introduction 
Chronic obstructive pulmonary disease (COPD) is a worldwide clinical burden1121. It is 
associated with high mortality31 and deterioration of quality of life41• COPD is a disease with 
multiple comorbidities, and the updated Global Initiative for Chronic Obstructive Lung Disease 
(GOLD 2015) stresses the importance of treating comorbidities in patients with COPD11. Two 
of the most common and least-treated comorbidities of COPD are anxiety and depression51, but 
only a few prospective studies have addressed the diagnosis and management of anxiety and 
depression, or have determined their impacts on health status among patients with COPD. 
Furthermore, only a very small number of studies have evaluated therapeutic approaches to 
anxiety and depression in COPD patients6171• 
Laughter is a behavior commonly related to positive emotion in human beings. Laughter is 
thought to be good for health, but the clinical application of laughter is challenging. Laughter 
yoga is an exercise that combines laughter with yoga breathing. It has become a worldwide 
health movement. with more than 10000 laughter clubs spread throughout numerous countries81. 
Laughter yoga originated with Dr. Madan Kataria, in 1995, in Mumbai, India. It does not require 
any specific inducer for laughter. Instead, participants may begin by feigning laughter until 
they begin to laugh mirthfully. We believed that laughter yoga might help to relieve the anxiety 
or depressive symptoms associated with COPD. Therefore, we performed a small, randomized 
pilot study to investigate the effect of laughter yoga during a pulmonary rehabilitation program 
in patients with COPD. 
To our knowledge, this is the first report of preliminary prospective randomized study of 
laughter yoga for COPD patients. 
Materials and Methods 
Participant: The participants were stable COPD patients from our outpatient clinic. The 
patients were enrolled in a pulmonary rehabilitation program. All patients who participated in 
the study gave written informed consent. Inclusion criteria were forced expiratory volume in 1 
second% predictive value (FEV1%) < 0.7 and FEV1%pred < 0.8, which are the GOLD 2 criteria. 
Patients with severe heart disease, neuromuscular disease, or dementia were excluded. The 
study participants were divided randomly using a sealed-envelope method into two groups: the 
laughter yoga (L Y) group and control group, which consisted of patients who participated in 
pulmonary rehabilitation without laughter yoga. All participants were enrolled in the pulmonary 
rehabilitation program for 2 weeks. There were 5 patients in the L Y group and 3 in the control 
group. The clinical trial was approved by the Yoshino-cho National Health Insurance Yoshino 
Hospital ethics committee. 
Assessment instruments: Base-line characteristics were assessed through a detailed 
questionnaire analysis of symptoms, age, smoking history, and diet. Height and body weight 
were measured. Spirometric analysis (MINATO Autospiro AS 507) was used to assess 
slow vital capacity (VC), forced vital capacity (FVC), and forced expiratory volume in one 
EFFECT OF LAUGHTER YOGA ON PULMONARY REHABILITATION IN 
PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (13) 
second (FEV1) using the Japanese Respiration Society (JRS) standard technique 91. Depressive 
symptoms were assessed by Self-rating Depression Scale (SDS) 101 and anxiety symptoms were 
assessed by the State-Trait Anxiety Inventory (ST AI) 111 for anxiety. The ST AI measures 
two aspects of anxiety: state anxiety is short term anxiety induced after a precipitating event 
and, trait anxiety is characteristic anxiety by nature. Health-related quality of life (QOL) was 
assessed by the Medical Research Council Health Survey Short Form 36-item (SF-36) 12>141, and 
the St. George's Respiratory Questionnaire (SGRQ) 151. The SF-36 is a generic instrument for 
QOL surveys, and the SGRQ is a disease-specific instrument for r espiratory failure. 
Exercise capacity assessment was done on the basis of the 6-minute walk test (6MD) 
according to the manual for respiratory rehabilitation of the Japanese Society for Respiratory 
Care and Rehabilitation 161. 
Intervention: All participants underwent comprehensive pulmonary rehabilitation (PR), which 
included a PR conference once a week. The exercise intensity was low to medium. There were 
five patient education sessions provided by a nurse using video lectures in a 2-week PR period. 
Drug education or nutritional education was offered when necessary. The patients in the L Y 
group had 10 min of laughter yoga before a standard PR exercise training session. The laughter 
yoga sessions involved the following steps: 
· Deep breathing (expiration-inspiration-expiration), 3 times. After inspiration a 3-second breath-
hold, followed by expiration with laughter. 
· Parallel hand clapping with full expanded finger-to-finger and palm-to-palm contact; Kataria 
has explained that this stage stimulates acupressure points in the hands to increase energy 
levels. This clapping is carried out rhythmically, i.e., 1-2, 1-2-3. 
·Laughter activities such as hand-shake laughter, wherein participants are to shake each other' 
s hands and laugh together. An important point of this step is eye contact; the participants are 
encouraged to maintain eye contact and laugh together. 
· The leader signals the end of the laughing activity by clapping and calling HO-HO HA-HA-
HA, and the participants stop their laughter. 
· The session covers 3 to 5 activities held over about 10 minutes. 
· Cool down at the end of these session by deep breathing. 
Data analysis: The data were analyzed using Stat View version 5.0 (SAS Institute Inc.) for 
Windows. Descriptive statistics were reported in tables and as mean ± standard deviation or 
frequency and percentage values. Main outcomes were presented as box plot graphs. Analyses 
of pre-post comparisons were performed using in Student's t-test and p-values of ~ 0.05 were 
considered significant. 
Results 
Patients characteristics are shown in Table 1. There were 5 patients in the L Y group and 
3 patients in the control group. There were no significant differences in age, body mass index 











Atsuhiko FUKUOKA et al. 
Table 1. Patient characteristics in 8 COPD patients 
Participants Laughter yoga Control group p value 
(n=8) group(n=S) (n=3) 
Age fyr] 75.5±6.4 74.6±6.7 77.0 ±7.0 
Male/Female 7/ 1 5/0 2/ 1 
BMI fkg/m'J 21.0±4.8 21.7±1.7 19.8±8.5 
VCfL) 2.54±0.59 2.58±0.30 2.47±1.00 ns 
FEV1 !L) 1.03±0.48 0.93±0.20 1.20±0.81 
6MD Iml 325.4±90.3 336.4±113.6 307.0±44.3 ns 
mM RC 2.86±0.69 2.75±0.5 3.00±1.0 ns 
[Table 1 abbreviation] 
BM!: Body mass index, VC:vita! capacity, FEV1 :forced expiratory volume in one second 
6MD: &-minute walk test, mM RC: modified Medical Research Council dyspnea scale 
Table 2. Questionnaire data befor e and after intervention 
Laughter yoga group Control group 
Pre-Rehab Post-Rehab Pre-Rehab 
SGRQ symptom 52.7±11.4 44.4±15.9 61.0±10.6 
SGRQ activity 70.6 ±18.9 68,0±20.6 70.7 ± 8.1 
SGRQ impacts 37.3±14.7 28.6±9.5* 42.7 ± 6.4 
SGRQ total 49.8±13.4 43.3±10.5 54.0± 4.4 
SF-36 PF 45.0± 31.4 53.3±29.2 41.1± 12.1 
SF-36 RP 15.0±33.5 30.0±41.1 8.3±14.4 
SF-36 BP 64.2±27.5 55.4± 25.3 54.7±15.8 
SF-36 GH 39.4±8.9 52.2±8.7* 40.7±9.8 
SF-36 VT 51.0± 18.2 62.0± 14.8 50.0 ±8.7 
SF-36SF 65.0±38.9 79.9±28.9 75.0± 21.7 
SF-36 RE 20.0±44.7 20.0±44.7 0.0± 0.0 
SF-36 MH 56.0±26.8 72.0±16.5 54.7± 8.3 
SOS 40.0±4.8 38.8± 9.9 40.7± 9.5* 
STAI(Stateamliety) 38.6± 12.4 35.0± 10.4 44.3 ± 11.7 
STAI(Trait anxiety) 33.8±5.4 31.2±8.6 41.0±13.0 
[Table 2 abbreviation] 
PF: physical functioning, RP: role-physical, BP: bodily pa in, GH: general health, Vf: 
vitality, SF: social functioning, RF: role-emotional, MH: mental health. 
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Fig. 1. QOL (SGRQ impacts domain) ch ange 
before and after intervent ion. LY group improved 
significantly, compar ed to the control group. 
SF36 PF SF36 PF 
Pre-rehab Post-rehab 
F ig. 2. QOL (SF-36 PF domain) change before 
and after inter vention. Control group improved 
significantly, compared to the LY group. The QOL 
of the control group was not different from that of 
the L Y group. 
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Fig. 3. Change in psychological QOL domains before and after 
intervention for 3-A. SF-36 General Health, 3-B. SF-36 Vitality, 3-C. 
SF-36 Mental Health. In 3-A. only GH is significantly improved in 
the L Y group. 
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STAI (Trait anxiety) 
Fig. 4. Depressive state and anxiety before and after intervention 
for 4-A. SDS score, 4-B. STAI (State anxiety) score, 4-C. ST AI (Trait 
anxiety)' score. There is no significant change in any data pre and 
post intervention. 
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The questionnaire data before and after intervention for each group are shown in Table 2. 
There was significant improvement in the SGRQ impacts domain in the LY group (37.3 ± 14.7 
to 28.6 ± 9.5. p = 0.023) (Fig. 1). but no significant change was noted in the control group. The 
SF-36 general health domain also improved significantly in the L Y group (39.4 ± 8.9 to 52.2 ± 
8.7, p = 0.016). but not in the control group (Fig. 3-A). The SF-36 physical functioning domain 
showed an improvement in both groups, but the change did not reach statistical significance in 
the LY group (45.0 ± 31.4 to 53.3 ± 29.2, p = 0.093, vs. 41.1 ± 12.1 to 46.7 ± 11.5. control group, 
p = O.OlO)(Fig. 2). 
There were no significant changes in SDS and ST AI outcomes from baseline to post-
rehabilitation (Fig. 4) in either group. 
Pre- and post-intervention, respiratory function, activity, and dyspnea scales are shown in 
Table 3. VC and FEV1 data did not change significantly in either group, and there were no 
significant changes in 6MD in either group, although the improvement in the control group was 
somewhat larger than that in the L Y group. The dyspnea scale had a tendency of improvement 
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Table 3. Respiratory function, activity, and dyspnea scale 
before and after intervention 
Laushter yos:a Grou~ Control !i,!;rDUE! p-value 
Pre-Rehab Post-Rehab Pre-Rehab Post-Rehab 
VC (l) 2.58±0.30 2.59±0.28 2.47±1.01 3.06±0.09 ns/ns 
FEV1 (l] 0.93±0.20 0.88±0.22 1.20±0.81 1.69±0.52 ns/ns 
IC Ill 1.79± 0 .16 1.99±0.47 1.71±0.84 1.97±0.50 ns/ns 
6MD (m] 336.4±113.6 339.6±128.1 307.0±44.2 337.7±23.7 ns/ns 
mM RC 2.75±0.50 2.00±0.0 3.00±1.00 2.67±0.58 ns/ ns 
(Table 3 abbreviation] 
VC: vital capacity, FEV1: forced expiratory volume in one second, IC: inspiratory 
capacity, GMD: 6-minute walk test, mM RC: modified Medical Research Council 
dyspnea scale 
in both groups, particularly in the L Y group (2.75 ± 0.50 to 2.00 ± 0.0, p = 0.057). 
Discussion 
In recent years, more attention has been focused on the many comorbid conditions in 
patients with COPD11• The GOLD 2015 and other guidelines emphasize the importance of the 
treatment for these comorbid diseases. Among the comorbidities, depression and anxiety are 
especially difficult to treat51• Depression is reported in 5.5 to 44.4% of patients with COPD171'231• 
The GOLD 2015 recommends standard medical therapies for depression and anxiety in patients 
with COPD, but this therapy is often not effective for these patients. Y ohannes et al.61 reported 
a trial of fluoxetine in depressive patients with COPD. They found that patient compliance 
with the antidepressants was poor. There were 7 out of 57 patients (12%) who completed a 
6-week course of fluoxetine, and 4 (7%) were fluoxetine responders. It was also reported in 
another study comparing COPD and non-COPD patients that 52.8% of the COPD patients were 
able to complete a 3-month course of antidepressants, vs. 63.2% of non-COPD patients 71, and 
Jordan et al. 241 have reported that there was no significant improvement in hospitalization and 
in all-cause mortality in COPD patients treated for depression in accordance with guideline 
recommendations. 
On the other hand, it is widely known that pulmonary rehabilitation is effective to relieve 
depression and anxiety for patients with COPD 251· 261• However depressed COPD patients 
may avoid attending pulmonary rehabilitation or have a greater tendency to drop out 271. It is 
possible that by enhancing the impression of these programs as a good life event, patients with 
depression and anxiety might be more likely to continue. 
The old proverb "laughter is the best medicine" had gained empirical support in various 
fields of medicine and health care. Norman Cousins, a well-known journalist in the US, published 
an article in the New England Journal of Medicine describing his successful pain relief for 
ankylosing spondylarthrit is, wherein he reported that 10 minutes of laughter give him at 
least two hours of pain-free sleep 281, and more recently it was determined that laughter could 
activate NK activity in various situations 291• 
Meanwhile, Surwit et al. have reported that negative emotion is associated with increased 
blood sugar levels 301, while Hayashi et al. have reported that laughter lowered postprandial 
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blood glucose levels in patients with type 2 diabetes mellitus after 40 min of watching Manzai, 
a Japanese cross-talk comedy 31' . Other studies have also indicated that laughter is effective in 
ameliorating type 2 diabetes mellitus 32· 33' . 
It has also been well-established that negative emotional states increase the risk for 
cardiovascular disease, and Sugawara et al. 34' have suggested that mirthful laughter had a 
beneficial effect on carotid arterial compliance, and that the effect was sustainable for 24 hours. 
Although all of these reports suggest the benefits of laughter or positive emotions, almost all 
studies concerning laughter have relied on comedy videos induce laughter in the test patients. 
In routine clinical practice, it can be difficult to accumulate a sufficient variety of comedy videos 
to maintain the interest of the patients. 
As noted, Madan Kataria introduced laughter yoga in 1995, while he was practicing as a 
family physician in Munbai, India. Laughter yoga combines laughter with a yoga breathing 
method. An advantage of laughter yoga is that it does not require an outside stimulate to 
induce laughter. Laughter yoga has recently been mentioned in several reports. Shahidi et al. 
found that the benefits of laughter yoga were equivalent to those of a group exercise program 
for elderly depressed women 35'. and laughter yoga has also been credited as beneficial for 
moderating heart rate variability, mood, and long-term anxiety among outpatients awaiting 
organ transplantation 36' . 
In this pilot study, laughter yoga provided significant improvements in the SGRQ 
impacts domain and the SF-36 general health domain among COPD patients in a pulmonary 
rehabilitation program. We believe that our finding that the SF-36 physical functioning domain 
was significantly improved only in the control group was due to the fact that the LY group had 
slightly higher baseline scores for this parameter, which may have influenced the extent of the 
difference in the change between the two groups before and after intervention. 
Our results showed a worsening tendency in the SDS score among the control patients, 
while there was a small (non-significant) decrease in these scores among the L Y patients, and 
state anxiety decreased in both groups, but not significantly. There was no significant change 
in VC, FEV~o or 6MD in either group. Since it is generally known that an effective duration for 
a pulmonary rehabilitation program is over 6 weeks 37'. the short study period in this report 
probably influenced these results. Taking this into account, our new 6-week COPD outpatients 
PR trial is under way. (Data was not shown in this paper.) 
The key to treating depression and anxiety in COPD patients remains elusive. If laughter 
yoga can provide improved psychological QOL, it will be a useful addition to pulmonary 
rehabilitation for COPD patients. 
We know that this study has several limitations. First, the number of patients is very small. 
We recently introduced an action plan for our pulmonary rehabilitation program that would 
have forced the study protocol to change, so we stopped entry into this study. 
Second. the SDS and ST AI scores did not change significantly, and this may be because 
among the enrolled patients, who came from our general COPD outpatient population, the 
baseline levels of depression and anxiety were lower than they would have been if we had 
focused enrollment on COPD patients with known depression and anxiety. Laughter yoga is 
very easy to perform, and may be beneficial for COPD patients with depression and anxiety. 
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Further studies with longer trial periods and greater numbers of COPD patients with known 
depression or anxiety should be encouraged. 
Conclusions 
The findings from this study reveal that laughter yoga may improve the psychological 
quality of life in patients with COPD. More studies need for establishing clinical usefulness of 
laughter yoga. We are very keen to improve the quality of life of patients with COPD using 
pulmonary rehabilitation with laughter yoga. 
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